Loading
A Beijing cancer genomics company that launched HIFI Pan-Cancer Screening, a whole-genome blood test for six cancers, in 2022.
Berry Oncology Corporation, whose staff give a Beijing address in their papers, publishes cell-free DNA tests for single cancers (liver, pancreatic, oesophageal, nasopharyngeal) and announced HIFI Pan-Cancer Screening for six cancers on 23 June 2022, with company-reported accuracy figures.
Berry Oncology's blood test for six cancers common in China, launched in 2022; its accuracy figures are the company's own and no peer-reviewed multi-cancer paper was found.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/